IP Library Granted Patent US 10,940,259
Granted Patent B2
US 10,940,259 · App. 16/171,089 · Granted Mar 9, 2021

Processing blood

Inventors: David Peritt (Skokie, IL); Philip Wong (Cremorne, AU); Janet Lesley Macpherson (Leichhardt, AU); Kevin Henrichsen (Shamong, NJ); Geoffrey Phillip Symonds (Rose Bay, AU); Susan Pond (Kirribilli, AU)
Assignee: Mallinckrodt Hospital Products IP Limited
A61M1/3496A61M1/362A61M1/3616A61M1/3626A61M1/3672A61M1/3689A61M1/3696A61M1/38B03C1/015B04B5/10B04B11/02A61M2202/0064A61M2202/0439
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,940,259
App. No.
16/171,089
Granted
Mar 9, 2021
Kind
B2
Abstract

Methods ( 300 ), devices, and systems of processing blood are described. The method ( 300 ) comprises the steps of: obtaining ( 312 ) blood from a patient coupled to a single blood processing device to form a closed loop between the patient and the blood processing device; collecting ( 314 ) bulk mononuclear blood cells from the blood by leukapheresis implemented using the blood processing device in the closed loop; and enriching ( 316 ) concurrently target cells separated from non-target cells in the bulk mononuclear blood cells using the blood processing device in the closed loop.

Claims (35)

1. An apparatus for processing blood, said apparatus comprising:

an inlet interface for coupling with a patient to receive blood directly from the circulation of said patient;

a leukapheresis module coupled to said inlet interface for collecting bulk mononuclear blood cells from said received blood;

an enrichment module coupled to said leukapheresis module for enriching concurrently target cells separated from non-target cells in said bulk mononuclear blood cells;

a target-cell modification module adapted to provide gene modification coupled to at least one of said leukapheresis module and said enrichment module, said modification module modifying said enriched target cells;

an outlet interface coupled to at least one of said leukapheresis module and said enrichment module for coupling with said patient to return enriched target cells to the circulation of said patient, said apparatus and said patient forming a closed loop when coupled together; and

a controller for automated control of operation of said inlet and outlet interfaces, said leukapheresis module, and said enrichment module.

2. The apparatus as claimed in claim 1 , wherein said controller comprises: a memory for storing data and instructions for automated control of operation of said inlet and outlet interfaces, said leukapheresis module, and said enrichment module; and a processor coupled to said memory capable of accessing said data and said instructions, said processor adapted to perform said instructions for automated control of operation of said inlet and outlet interfaces, said leukapheresis module, and said enrichment module.

3. The apparatus as claimed in claim 1 , further comprising means for returning said modified target-cells to said patient.

4. The apparatus as claimed in claim 1 , further comprising at least one pump for circulating at least a portion of said blood within said apparatus.

5. The apparatus as claimed in claim 4 , further comprising a pump and at least one valve coupled to said inlet interface for providing said blood to said leukapheresis module and another pump and at least one valve coupled to said outlet interface for returning blood from said apparatus.

6. The apparatus as claimed in claim 1 , wherein said leukapheresis module comprises a centrifuge bowl that uses differential centrifugation to collect said mononuclear blood cells.

7. The apparatus as claimed in claim 1 , wherein said differential centrifugation is conducted by a continuous flow system.

8. The apparatus as claimed in claim 1 , wherein the target cells are hematopoietic progenitor cells.

9. The apparatus as claimed in claim 1 , wherein the target cells are mesenchymal cells.

10. The apparatus as claimed in claim 1 , wherein the target cells are T lymphocytes.

11. The apparatus as claimed in claim 1 , wherein the target cells are B lymphocytes.

12. The apparatus as claimed in claim 1 , wherein the target cells are monocytes.

13. The apparatus as claimed in claim 1 , wherein the target cells are dendritic cells.

14. A system for processing blood, said system comprising:

means for obtaining blood from a patient; and

a single blood processing device coupled to said obtaining means and said patient to form a closed loop between said patient and said blood processing device, said blood processing device comprising:

means for collecting bulk mononuclear blood cells from said blood by leukapheresis implemented using said blood processing device in said closed loop;

means for enriching concurrently target cells separated from nontarget cells in said bulk mononuclear blood cells using said blood processing device in said closed loop; and

means for genetically modifying target cells in said closed loop.

15. The system as claimed in claim 14 , further comprising means for discarding said non-target cells.

16. The system as claimed in claim 14 , further comprising means for concurrently monitoring the collecting and enriching of said collecting and enriching means, respectively.

17. The system as claimed in claim 14 , wherein said collecting means uses differential centrifugation to collect said mononuclear blood cells and said enriching means uses ligand capture to enrich said target cells.

18. The system as claimed in claim 17 , wherein said ligand is an antibody specific for a cell surface ligand.

19. The system as claimed in claim 14 , wherein the target cells are hematopoietic progenitor cells.

20. The system as claimed in claim 14 , wherein the target cells are mesenchymal cells.

21. The system as claimed in claim 14 , wherein the target cells are T lymphocytes.

22. The system as claimed in claim 14 , wherein the target cells are B lymphocytes.

23. The system as claimed in claim 14 , wherein the target cells are monocytes.

24. The system as claimed in claim 14 , wherein the target cells are dendritic cells.

Assignments (23)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2026
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED COMPANY
Reel/Frame 075393/0921 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2026
From: THERAKOS DEVELOPMENT LIMITED
To: THERAKOS HOLDINGS USA, LLC
Reel/Frame 075227/0886 →
RELEASE OF PATENT SECURITY INTEREST RECORDED AT REEL 69476, FRAME 0380 Recorded Mar 17, 2026
From: NOMURA CORPORATE FUNDING AMERICAS, LLC, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
To: THERAKOS DEVELOPMENT LIMITED
Reel/Frame 075101/0970 →
PATENT SECURITY AGREEMENT Recorded Mar 17, 2026
From: THERAKOS HOLDINGS USA, LLC
To: NOMURA CORPORATE FUNDING AMERICAS, LLC, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 075102/0334 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: THERAKOS DEVELOPMENT LIMITED
Reel/Frame 070623/0743 →
RELEASE OF SECURITY INTERESTS Recorded Dec 3, 2024
From: ACQUIOM AGENCY SERVICES, LLC, AS COLLATERAL AGENT
To: MALLINCKRODT PHARMA IP TRADING LIMITED; STRATATECH CORPORATION; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 069476/0103 →
PATENT SECURITY AGREEMENT Recorded Dec 3, 2024
From: SOLARIS IPCO LIMITED
To: NOMURA CORPORATION FUNDING AMERICAS, LLC, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 069476/0380 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2024
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 069127/0749 →
CHANGE OF NAME Recorded Nov 4, 2024
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
Reel/Frame 069301/0664 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0454 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
NUNC PRO TUNC ASSIGNMENT Recorded Aug 14, 2019
From: THERAKOS, INC.
To: MALLINCKRODT CRITICAL CARE FINANCE INC.
Reel/Frame 050056/0042 →
NUNC PRO TUNC ASSIGNMENT Recorded Aug 14, 2019
From: MALLINCKRODT PHARMA IP TRADING D.A.C.
To: MALLINCKRODT IP
Reel/Frame 050056/0219 →
NUNC PRO TUNC ASSIGNMENT Recorded Aug 14, 2019
From: MALLINCKRODT IP
To: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
Reel/Frame 050056/0303 →
NUNC PRO TUNC ASSIGNMENT Recorded Aug 14, 2019
From: MALLINCKRODT CRITICAL CARE FINANCE INC.
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 050056/0122 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jul 22, 2019
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 049822/0674 →
Cited By (1)
US 12,447,253